A-Z Index × Submit A-Z Index × Submit A-Z Index Search Dropdown × Submit Facebook Twitter LinkedIn Syndicate Emerging Infectious Disease journal ISSN: 1080-6059 Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Bundibugyo virus disease (BVD), an Ebola virus species with no licensed vaccine or therapeutic, reemerged in May 2026 as a cross-border outbreak in Uganda and the Democratic Republic of the Congo. During a 2-day workshop, July 8–9, 2026, we conducted an early action review of the outbreak response using the 7-1-7 framework (7 days to detect, 1 day to notify, 7 days to complete early response actions) to assess timeliness and identify bottlenecks and enablers across 9 response pillars. Uganda declared its outbreak on May 15, 2026; by July 8, the country had recorded 20 confirmed cases (15 imported, 5 locally transmitted) and a case-fatality rate of 15%. Uganda met all 3 targets: detection in 6 days, notification in <1 day, and response completion in 2 days. Low clinical suspicion, cross-border data-sharing gaps, fragmented digital systems, and delayed community engagement were common bottlenecks; strong leadership and coordination structures were most cited enablers.
Bundibugyo virus disease (BVD) is a severe viral hemorrhagic fever caused by Orthoebolavirus bundibugyoense , a documented Ebola virus species. The virus was first identified during a 2007 outbreak in Bundibugyo District, western Uganda ( 1 ); that outbreak ultimately comprised 131 cases, including 56 laboratory-confirmed cases and a case-fatality rate (CFR) of 40% among confirmed cases ( 2 – 4 ). Bundibugyo virus subsequently caused a second confirmed outbreak, in the Democratic Republic of the Congo (DRC) in 2012, comprising 62 cases, including 36 laboratory-confirmed cases and a CFR of 33% among confirmed cases ( 5 ). Reported CFRs for BVD are generally lower than for Ebola caused by Zaire ebolavirus ( 6 ). Unlike other Ebola virus species, no licensed vaccine or approved specific therapeutic currently exists for BVD, although licensed Zaire ebolavirus vaccines show early evidence of partial cross-reactive immunogenicity, and candidate BVD-specific vaccines and therapeutics are undergoing World Health Organization (WHO)–led prioritization ( 7 – 11 ).
On May 15, 2026, both Uganda and the DRC declared separate outbreaks, a transboundary BVD event, from which cases were epidemiologically linked to Ituri Province, DRC ( 12 ). Uganda’s index case, a 59-year-old DRC national, sought care at a private hospital in Kampala on May 11, 2026, and died on May 14, 2026 ( 13 ). On May 17, 2026, WHO determined the event constituted a Public Health Emergency of International Concern under the International Health Regulations 2005 ( 14 ), and on May 18, 2026, the Africa Centres for Disease Control and Prevention declared the outbreak a Public Health Emergency of Continental Security ( 15 ). By July 8, 2026, Uganda had recorded 20 confirmed cases, of which 15 were directly imported from the DRC, underscoring the cross-border nature of the outbreak and the need for sustained joint surveillance and coordinated screening along the Uganda–DRC corridor.
The 7-1-7 target, defined as < 7 days to detect a suspected outbreak, < 1 day to notify relevant public health authorities, and < 7 days to complete essential early response actions, was jointly developed by WHO a…